Conjugates of biologically active proteins having a modified in vivo half-life
AssigneeCell Therapeutics, Inc.
InventorsMarc Besman, Stewart Chipman, David Leung, Jack Singer
Life of this patent
Estimating the term…
Loading patent…
AssigneeCell Therapeutics, Inc.
InventorsMarc Besman, Stewart Chipman, David Leung, Jack Singer
Estimating the term…
Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.
1-46. (canceled)
A biologically active protein conjugate comprising a biologically active polypeptide coupled via a peptide bond to an amino acid extension comprising from 2 to 250 repeating units of a peptide motif, wherein said peptide motif consists of two residues Asn (N) and one residue of an amino acid selected from the group consisting of Ser (S) and Thr (T), and wherein said biologically active protein conjugate has an increased plasma half-life compared to the plasma half-life of the unmodified biologically active polypeptide.
A method of making a biologically active protein conjugate comprising a biologically active polypeptide coupled via peptide bond to an amino acid extension comprising from 2 to 500 units of a repeating units of peptide motif, wherein said peptide motif consists of two residues Asn (N) and one residue of an amino acid selected from the group consisting of Ser (S) and Thr (T), and wherein said biologically active protein conjugate has an increased plasma half-life compared to the plasma half-life of the unmodified biologically active polypeptide, said method comprising:
A method of determining whether a biologically active protein conjugate exhibits an increased plasma half-life compared to the plasma half-life of an unmodified biologically active polypeptide, comprising:
A method for increasing the plasma half-life of a biologically active polypeptide as compared to the plasma half-life of the unmodified biologically active polypeptide, comprising coupling to the biologically active polypeptide via a peptide bond an amino acid extension comprising from 2 to 250 repeating units of a peptide motif, wherein said peptide motif consists of two residues of Asn (N) and one residue of one amino acid selected from the group consisting of Ser (S) and Thr (T), whereby said biologically active protein conjugate has an increased plasma half-life compared to the plasma half-life of the unmodified biologically active polypeptide.
Dependencies are inferred from the claim text.